Hallo! Tracked shipping to Austria with Delivery Duty Paid for just €3.99  

Ship to
Austria
0

My Account

  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

menu

Select your country

Americas

Europe

Rest of the world

portada A New Approach for Understanding the Mechanism and Drug Design of Chronic Myeloid Leukemia Responsive Protein: An In-Silico Study for the Design of Is
Type
Physical Book
Author
Publisher
Language
English
Pages
50
Format
Paperback
Dimensions
22.9x15.2x0.3 cm
Weight
0.08 kg.
ISBN13
9781952751516
Categories

A New Approach for Understanding the Mechanism and Drug Design of Chronic Myeloid Leukemia Responsive Protein: An In-Silico Study for the Design of Is

Gyan Prakash Rai (Author) · Alvea Tasneem (Author) · Saima Reyaz (Author) · Eliva Press · Paperback

A New Approach for Understanding the Mechanism and Drug Design of Chronic Myeloid Leukemia Responsive Protein: An In-Silico Study for the Design of Is - Prakash Rai, Gyan ; Tasneem, Alvea ; Reyaz, Saima

New Book Imported to Austria
Delivery: 14 Sep - 21 Sep Shipping: 16 to 20 business days.
48,55 €
Import costs and 10% VAT included in the price ✅
48,55 €

Choose the list to add your product or create one New List

Go to My Wishlists
Calculate shipping cost

Synopsis "A New Approach for Understanding the Mechanism and Drug Design of Chronic Myeloid Leukemia Responsive Protein: An In-Silico Study for the Design of Is"

Chronic myeloid leukemia (CML) is a blood cancer. In CML cancer, stem cells of bone marrow form abnormal WBCs that hinder the function of normal RBCs and WBCs. CML occurs due to a chromosomal translocation between BCR gene on Chromosome-22 and ABL gene on Chromosome-9. The purine nucleotide biosynthesis pathway consists of three enzymes (hIMPDH, hGMPS and hGMPR) which are identified to be responsible for CML cancer and they are also involved in cellular metabolic pathways that exhibit elevated levels of activity in rapidly proliferating cells, such as neoplastic and regenerating tissues. These CML responsive proteins exist as type-I and II isoforms. Isoform-II is responsible for CML cancer, whereas isoform-I which keeps a housekeeping role, and observed in normal cells. Our in-silico methods may explore some new biochemical mechanism and novel conformation of this protein that may be effective for future drug discovery. The basic problem for discovery of drugs for CML cancer protein is that all proposed inhibitors bind to CML cancerous and normal protein, as a result both normal and cancer cells lose their function and die. To design the drugs for CML cancerous protein, isoform specific (type-II) drug design techniques were employed in this study and the new inhibitors were identified by computational method using different databases. The computationally designed proposed drugs can be effective to recognize the CML cancer protein and may act as a good drug candidate for CML cancer.

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

Is the book original?

All books in our catalog are Original.

In what language is the book written?

The book is written in English.

What is the format of this book?

The binding of this edition is Paperback.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews